A long-term, open-label study of valbenazine for tardive dyskinesia / Jean-Pierre Lindenmayer en CNS Spectrums, Año 2021 Vol. 26 - No. 4 (Agosto) 

Público ISBD [artículo]  inCNS Spectrums > Año 2021 Vol. 26 - No. 4 (Agosto) . - pp. 345 - 353 Título : A long-term, open-label study of valbenazine for tardive dyskinesia Tipo de documento: texto impreso Autores: Jean-Pierre Lindenmayer, Autor ; Cherian Verghese, Autor ; Stephen R. Marder, Autor Fecha de publicación: 2022 Artículo en la página: pp. 345 - 353 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Discinesia tardía, Valbenazina, Inhibidor de VMAT2, Antipsicóticos, Esquizofrenia, Trastorno del estado de ánimo Resumen: Individuals with tardive dyskinesia (TD) who completed a long-term study (KINECT 3 or KINECT 4) of valbenazine (40 or 80 mg/day, once-daily for up to 48 weeks followed by 4-week washout) were enrolled in a subsequent study (NCT02736955) that was primarily designed to further evaluate the long-term safety of valbenazine. Link: ./index.php?lvl=notice_display&id=28341 [artículo] A long-term, open-label study of valbenazine for tardive dyskinesia [texto impreso] / Jean-Pierre Lindenmayer, Autor ; Cherian Verghese, Autor ; Stephen R. Marder, Autor . - 2022 . - pp. 345 - 353. Idioma : Inglés (eng) Idioma original : Inglés (eng) in CNS Spectrums > Año 2021 Vol. 26 - No. 4 (Agosto) . - pp. 345 - 353 Palabras clave: Discinesia tardía, Valbenazina, Inhibidor de VMAT2, Antipsicóticos, Esquizofrenia, Trastorno del estado de ánimo Resumen: Individuals with tardive dyskinesia (TD) who completed a long-term study (KINECT 3 or KINECT 4) of valbenazine (40 or 80 mg/day, once-daily for up to 48 weeks followed by 4-week washout) were enrolled in a subsequent study (NCT02736955) that was primarily designed to further evaluate the long-term safety of valbenazine. Link: ./index.php?lvl=notice_display&id=28341

A randomized, double blind, parallel-group, fixed dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment resistant schizophrenia or schizoaffective disorder / Jean-Pierre Lindenmayer en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 2 (Abril)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 160-168 Título : A randomized, double blind, parallel-group, fixed dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment resistant schizophrenia or schizoaffective disorder Tipo de documento: texto impreso Autores: Jean-Pierre Lindenmayer, Autor ; Leslie L. Citrome, Autor ; Anzalee Khan, Autor Fecha de publicación: 2022 Artículo en la página: pp. 160-168 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Dosis altas de quetiapina, Esquizofrenia resistente al tratamiento Resumen: Quetiapine is often prescribed at doses higher than those approved by regulatory authorities, with limited evidence from controlled trials. The objective of this study was to assess the safety, tolerability, and efficacy of high-dose quetiapine (1200 mg/d) compared with a standard dose of 600 mg/d among patients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, schizophrenia or schizoaffective disorder hospitalized at 2 state-operated psychiatric facilities. Link: ./index.php?lvl=notice_display&id=29384 [artículo] A randomized, double blind, parallel-group, fixed dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment resistant schizophrenia or schizoaffective disorder [texto impreso] / Jean-Pierre Lindenmayer, Autor ; Leslie L. Citrome, Autor ; Anzalee Khan, Autor . - 2022 . - pp. 160-168. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 160-168 Palabras clave: Dosis altas de quetiapina, Esquizofrenia resistente al tratamiento Resumen: Quetiapine is often prescribed at doses higher than those approved by regulatory authorities, with limited evidence from controlled trials. The objective of this study was to assess the safety, tolerability, and efficacy of high-dose quetiapine (1200 mg/d) compared with a standard dose of 600 mg/d among patients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, schizophrenia or schizoaffective disorder hospitalized at 2 state-operated psychiatric facilities. Link: ./index.php?lvl=notice_display&id=29384

A randomized, double blind, placebo controlled study of 2 dose ranges of paliperidone extended release in the treatment of subjects with schizoaffective disorder / Carla M. Canuso en The Journal of Clinical Psychiatry, Año 2010 - Vol. 71 - No. 5 (Mayo)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2010 - Vol. 71 - No. 5 (Mayo) . - pp. 587-598 Título : A randomized, double blind, placebo controlled study of 2 dose ranges of paliperidone extended release in the treatment of subjects with schizoaffective disorder Tipo de documento: texto impreso Autores: Carla M. Canuso, Autor ; Jean-Pierre Lindenmayer, Autor ; Colette Kosik González, Autor Fecha de publicación: 2022 Artículo en la página: pp. 587-598 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Isoxazoles, Trastornos psicóticos, Pirimidinas. Resumen: This study was designed to assess efficacy and safety of paliperidone extended-release (ER) in patients with schizoaffective disorder. Link: ./index.php?lvl=notice_display&id=28188 [artículo] A randomized, double blind, placebo controlled study of 2 dose ranges of paliperidone extended release in the treatment of subjects with schizoaffective disorder [texto impreso] / Carla M. Canuso, Autor ; Jean-Pierre Lindenmayer, Autor ; Colette Kosik González, Autor . - 2022 . - pp. 587-598. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2010 - Vol. 71 - No. 5 (Mayo) . - pp. 587-598 Palabras clave: Antipsicóticos, Isoxazoles, Trastornos psicóticos, Pirimidinas. Resumen: This study was designed to assess efficacy and safety of paliperidone extended-release (ER) in patients with schizoaffective disorder. Link: ./index.php?lvl=notice_display&id=28188

A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia / Gahan J. Pandina en Journal of Clinical Psychopharmacology, Año 2010 - Vol. 30 - No. 3 (Junio)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 3 (Junio) . - pp. 235-244 Título : A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia Tipo de documento: texto impreso Autores: Gahan J. Pandina, Autor ; Jean-Pierre Lindenmayer, Autor ; Julia Lull, Autor Fecha de publicación: 2022 Artículo en la página: pp. 235-244 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicótico atípico, Deltoides, Dosis de inicio, Inyectable de acción prolongada, Palmitato de paliperidona, Esquizofrenia Resumen: This study assessed the efficacy and the safety of a dosing regimen that was revised from earlier studies for the investigational injectable atypical antipsychotic paliperidone palmitate (approved in the USA, August 2009) for adult patients with acutely exacerbated schizophrenia. Link: ./index.php?lvl=notice_display&id=29447 [artículo] A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia [texto impreso] / Gahan J. Pandina, Autor ; Jean-Pierre Lindenmayer, Autor ; Julia Lull, Autor . - 2022 . - pp. 235-244. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 3 (Junio) . - pp. 235-244 Palabras clave: Antipsicótico atípico, Deltoides, Dosis de inicio, Inyectable de acción prolongada, Palmitato de paliperidona, Esquizofrenia Resumen: This study assessed the efficacy and the safety of a dosing regimen that was revised from earlier studies for the investigational injectable atypical antipsychotic paliperidone palmitate (approved in the USA, August 2009) for adult patients with acutely exacerbated schizophrenia. Link: ./index.php?lvl=notice_display&id=29447

Schizophrenia with impulsive and aggressive behaviors / Jean-Pierre Lindenmayer en Psychiatric Clinics of North America, Año 2009 - Vol.32 No. 4 (Diciembre)

Público ISBD [artículo]  inPsychiatric Clinics of North America > Año 2009 - Vol.32 No. 4 (Diciembre) . - pp. 885-902 Título : Schizophrenia with impulsive and aggressive behaviors Tipo de documento: texto impreso Autores: Jean-Pierre Lindenmayer, Autor ; Isabella Kanellopoulou, Autor Fecha de publicación: 2020 Artículo en la página: pp. 885-902 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Esquizofrenia, Conducta impulsiva, Conducta agresiva, Intervenciones Resumen: Impulsive and aggressive behaviors are important clinical challenges in the treatment of patients with schizophrenia. They occur both in the acute phase as well as in the chronic phase of the disorder and call for differentiated treatment interventions. Link: ./index.php?lvl=notice_display&id=24450 [artículo] Schizophrenia with impulsive and aggressive behaviors [texto impreso] / Jean-Pierre Lindenmayer, Autor ; Isabella Kanellopoulou, Autor . - 2020 . - pp. 885-902. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Psychiatric Clinics of North America > Año 2009 - Vol.32 No. 4 (Diciembre) . - pp. 885-902 Palabras clave: Esquizofrenia, Conducta impulsiva, Conducta agresiva, Intervenciones Resumen: Impulsive and aggressive behaviors are important clinical challenges in the treatment of patients with schizophrenia. They occur both in the acute phase as well as in the chronic phase of the disorder and call for differentiated treatment interventions. Link: ./index.php?lvl=notice_display&id=24450

---

1 (1 - 5 / 5)